Form 4: Supernus CEO Exercises Options, Sells Shares
Insider Transaction Report
Supernus Pharmaceuticals CEO Jack Khattar exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.
Summary
- Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in transactions on October 1, 2025.
- Exercised employee stock options to acquire 53,785 shares of common stock at an exercise price of $25.30 per share.
- Subsequently sold 40,173 shares of common stock at a weighted average price of $48.07 per share, with prices ranging from $48.00 to $48.25.
- These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
- Following these transactions, Khattar directly owns 1,160,870 shares of common stock and indirectly owns 1,005,600 shares through the KBT Trust.
- Remaining unexercised employee stock options total 83,517, which vest in four equal installments beginning February 24, 2018, and expire on February 24, 2027.
Sentiment
Score: 6
Explanation: The transactions were pre-planned under a 10b5-1 plan, which mitigates the negative perception of insider selling. The executive realized a significant gain from exercising options and selling shares at a higher price, while still retaining a substantial stake.
Positives
- The executive realized a significant gain, selling shares at a weighted average price of $48.07 after exercising options at $25.30.
- The exercise of options indicates the executive is realizing value from their compensation, which can be seen as a positive sign of long-term commitment or belief in the company's value.
Negatives
- Insider selling, even under a pre-arranged plan, can sometimes be interpreted as a reduction in direct exposure to the company's stock by a key executive.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May view the sale as a slight reduction in direct insider exposure, but the pre-planned nature under a 10b5-1 plan generally reduces concerns about its implications for company performance. The executive retains a significant direct and indirect ownership stake.
Key Dates
| Date | Description |
|---|---|
| 2018-02-24 | Date employee stock option began vesting in four equal installments. |
| 2024-11-14 | Date Rule 10b5-1 trading plan was adopted. |
| 2025-10-01 | Date of stock option exercise and subsequent sale of common stock. |
| 2025-10-02 | Date of filing signature. |
| 2027-02-24 | Expiration date of the employee stock option. |
Recommendation
holdThe filing details a pre-planned insider transaction (option exercise and subsequent sale) by the CEO. While insider selling can sometimes be a negative signal, the execution under a Rule 10b5-1 plan adopted well in advance (November 2024 for an October 2025 transaction) suggests it's part of a personal financial management strategy rather than a reaction to new, negative company-specific information. The executive still retains a significant direct and indirect stake in the company. Therefore, this specific Form 4 filing alone does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position based solely on this information.
Keywords
Supernus Pharmaceuticals, SUPN, Jack Khattar, insider trading, stock options, 10b5-1 plan, CEO, Director, stock sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.